Literature DB >> 31545443

High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer.

Ryoichi Sawada1, Yoshinori Arai1, Yukiko Sagawa2, Yusuke Nagata1, Takashi Nishimura1, Masaaki Noguchi1, Katsushi Amano1, Seiji Arihiro1, Masayuki Saruta1, Sadamu Homma2.   

Abstract

The interaction between tumor necrosis factor receptor superfamily, member 4 (OX40) on T cells and the OX40 ligand (OX40L) on antigen‑presenting cells (APCs) is a pivotal step for T‑cell activation and the promotion of antitumor immunity. However, it is hypothesized that soluble OX40 (sOX40) in blood suppresses T‑cell activation by blocking the OX40/OX40L interaction. In the present study, the association between blood sOX40 levels and the clinical characteristics of advanced colorectal cancer (CRC) patients was investigated. Blood was collected from 22 patients with advanced CRC. Blood sOX40 levels were determined by enzyme‑linked immunosorbent assay (ELISA). Messenger RNA (mRNA) expression encoding OX40 or cytokines was analyzed by quantitative RT‑PCR. Blood sOX40 levels were positively correlated with the blood levels of carbohydrate antigen (CA) 19‑9, carcinoembryonic antigen (CEA), C‑reactive protein (CRP) and soluble programmed cell death ligand‑1 (PD‑L1) in patients but negatively correlated with the blood levels of albumin. Blood sOX40 levels were not correlated with the mRNA expression of interferon (IFN)‑gamma, interleukin (IL)‑6, IL‑10 and IL‑4 in the peripheral blood mononuclear cells (PBMCs) of the patients and were not correlated with the frequency of programmed cell death‑1 (PD‑1) expressing CD4+, CD8+ and CD56+ cells. Notably, according to both univariate and multivariate analyses, high blood sOX40 levels were significantly correlated with a reduced survival time in patients. Although activated Jurkat cells (a human T cell line) exhibited an upregulation of sOX40 production and OX40 mRNA expression, the OX40 mRNA expression of the PBMCs of patients was not correlated with blood sOX40 levels. High blood levels of sOX40 were correlated with a reduced survival time in patients with advanced CRC, possibly associated with the suppression of antitumor immunity by sOX40.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31545443     DOI: 10.3892/or.2019.7304

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Serum Levels of OX40 in Early and Late-Stage Oral Squamous Cell Carcinoma.

Authors:  Aliya I Sani; Zil E Rubab; Shumaila Usman; Syed Zaryab Ahmed; Mervyn Hosein; Moazzam A Shahid
Journal:  Cureus       Date:  2021-04-20

Review 2.  The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review.

Authors:  Yu Liu; Peixin Chen; Hao Wang; Shengyu Wu; Sha Zhao; Yayi He; Caicun Zhou; Fred R Hirsch
Journal:  Transl Lung Cancer Res       Date:  2021-02

Review 3.  The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs).

Authors:  Payam Behzadi; Aga Syed Sameer; Saniya Nissar; Mujeeb Zafar Banday; Márió Gajdács; Herney Andrés García-Perdomo; Kulsum Akhtar; Marina Pinheiro; Peter Magnusson; Meysam Sarshar; Cecilia Ambrosi
Journal:  J Immunol Res       Date:  2022-03-26       Impact factor: 4.818

4.  Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma.

Authors:  Xianlong Chen; Heng Ma; Shengwei Mo; Yue Zhang; Zhaohui Lu; Shuangni Yu; Jie Chen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

5.  Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma.

Authors:  Jiawei Zhang; Yinan Wu; Jiayi Mu; Dijia Xin; Luyao Wang; Yili Fan; Suzhan Zhang; Yang Xu
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

6.  Comprehensive analysis of Syk gene methylation in colorectal cancer.

Authors:  Fanqin Bu; Xiaojian Zhu; Sicheng Liu; Kang Lin; Jinfeng Zhu; Jun Huang
Journal:  Immun Inflamm Dis       Date:  2021-05-12

Review 7.  T-cell agonists in cancer immunotherapy.

Authors:  Yeonjoo Choi; Yaoyao Shi; Cara L Haymaker; Aung Naing; Gennaro Ciliberto; Joud Hajjar
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.